Madison Square Garden Sports Co (MSGS) Stock Price & How to Invest

Madison Square Garden Sports Corp. owns and operates the New York Knickerbockers of the NBA and the New York Rangers of the NHL, along with two development-league affiliates and a professional sports team performance business. Its revenue comes from ticket sales and premium seating, local media rights fees, sponsorship and signage, food and merchandise at games, and its share of leaguewide national media and licensing money. The company does not own Madison Square Garden itself: the arena sits inside MSG Entertainment, and the Knicks and Rangers pay to play there under long-term arrangements, which is why the reported financials look thinner than the size of the underlying assets suggests. Revenue for the trailing twelve months is roughly ~$1.08 billion against a market capitalization of about ~$9.4 billion, a ratio that only makes sense once you treat the company as an asset holder rather than an operating business.

The investment picture is dominated by the spread between accounting results and franchise value. Sportico's most recent valuations put the Knicks around ~$9.85 billion (third in the NBA) and the Rangers around ~$3.65 billion (second in the NHL), for a combined figure near ~$13.5 billion, while the equity trades at roughly ~$9.4 billion and the company has posted a small GAAP loss over the last twelve months. Historically that discount was explained by the control structure, the absence of a dividend, and the fact that no minority holder can force a sale of a team. In February 2026 the board approved exploration of a tax-free separation of the Knicks business from the Rangers business, and a confidential Form 10 was filed with the SEC in May 2026, which is the specific event that pulled the stock up roughly 93% over the past year to about ~$390 a share. What is being priced now is partly the assets and partly the probability that the structure changes.

The Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. The spin-off is exploratory: a confidential filing is not a commitment, and the transaction could be delayed, restructured or abandoned, in which case the narrowing of the discount could reverse. The company generates little in the way of reported profit (a trailing twelve-month net loss of about ~$22 million on ~$1.08 billion of revenue), so there is no earnings support underneath the price if franchise appraisals stop rising. Player compensation, collective bargaining outcomes and luxury-tax structures in both leagues can raise costs faster than revenue, and local media rights remain the softest part of the model. Finally, with roughly ~24 million shares outstanding, the float is small and the stock can move sharply on transaction headlines in either direction.

6 analysts publish price targets on MSGS, averaging $441.17 against a $389.99 price as of August 2026, or +13.1%. The published targets run from $360.00 to $522.00, a moderate spread, and the ratings split 5 buy, 3 hold, 0 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MSGS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Madison Square Garden Sports Co. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Franchise scarcity. There are 30 NBA teams and 32 NHL teams, and the two in the largest US media market almost never change hands. The most optimistic published target, $522.00, assumes this works close to its best case.

The case against. The Dolan family controls the company through Class B shares carrying ten votes each and the right to elect 75% of the board, so a minority holder has essentially no ability to force a sale, a buyback, a dividend or a change of management. The most pessimistic target, $360.00, is roughly what MSGS is worth if this bites instead.

Read the full bull and bear case on MSGS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Madison Square Garden Sports Co's investor relations page or your broker.

• Share price: ~$390
• Market capitalization: ~$9.4 billion
• Revenue (TTM): ~$1.08 billion
• Net income (TTM): ~-$22 million (EPS ~-$0.93)
• Franchise value estimate: ~$13.5 billion combined (Knicks ~$9.85B, Rangers ~$3.65B per Sportico)
• Shares outstanding: ~24.1 million (Class A plus Class B)

Conventional earnings multiples do not describe this stock: the company runs near breakeven on an accounting basis while holding assets appraised at several times its revenue. The more common framework is a sum-of-the-parts, comparing the market capitalization of about ~$9.4 billion against combined franchise appraisals near ~$13.5 billion and then adjusting for borrowings and for the discount attached to a controlled structure. That gap has narrowed considerably over the past year as the shares roughly doubled off a 52-week low near ~$189, so the spin-off outcome now carries more of the weight than the raw appraisal spread does.

Other names that sit close to MSGS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MSGS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so MSGS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MSGS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

MSGS is a franchise-value asset wrapped in a controlled corporate structure, and the whole debate is how much of that private-market value a minority public holder can actually reach.

Whether MSGS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MSGS a buy or a sell?, and where the stock could go from here in the MSGS stock forecast.

For income investors, whether MSGS pays a dividend and how the payout looks is covered in does MSGS pay a dividend? And to weigh MSGS against a peer, read the full side-by-side comparisons: MSGS vs BATRA and MSGS vs TKO.